deruxtecan
2 abstracts
Abstract
YB-800, a monoclonal antibody targeting the human neuronal pentraxin receptor (NPTXR), as a potential candidate for the design of a first in class antibody drug conjugate (ADC) as novel therapeutic intervention in gastro-intestinal cancers.Org: Ymmunobio, University Clinic Essen,
Abstract
Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC).Org: Syndax Pharmaceutials, Inc., Tariffville, CT,